VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 41 filers reported holding VERONA PHARMA PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102,983,237 | -22.9% | 6,317,990 | 0.0% | 2.03% | -19.6% |
| Q2 2023 | $133,562,309 | +5.3% | 6,317,990 | 0.0% | 2.52% | -12.2% |
| Q1 2023 | $126,865,239 | -23.2% | 6,317,990 | 0.0% | 2.87% | -14.2% |
| Q4 2022 | $165,089,079 | +167.0% | 6,317,990 | +4.4% | 3.35% | +153.8% |
| Q3 2022 | $61,831,000 | +189.3% | 6,050,000 | +18.6% | 1.32% | +131.4% |
| Q2 2022 | $21,369,000 | -16.0% | 5,100,000 | 0.0% | 0.57% | +2.7% |
| Q1 2022 | $25,449,000 | -25.7% | 5,100,000 | 0.0% | 0.56% | -8.1% |
| Q4 2021 | $34,272,000 | +22.6% | 5,100,000 | 0.0% | 0.60% | +56.1% |
| Q3 2021 | $27,948,000 | -16.2% | 5,100,000 | 0.0% | 0.39% | -27.7% |
| Q2 2021 | $33,354,000 | -21.8% | 5,100,000 | 0.0% | 0.54% | -16.8% |
| Q1 2021 | $42,636,000 | +34.0% | 5,100,000 | 0.0% | 0.64% | +44.5% |
| Q4 2020 | $31,824,000 | 0.0% | 5,100,000 | 0.0% | 0.44% | -23.5% |
| Q3 2020 | $31,824,000 | – | 5,100,000 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |